Status:
COMPLETED
A Lifestyle and Combination Medication Therapy Diabetes Prevention Study
Lead Sponsor:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Collaborating Sponsors:
University of Western Ontario, Canada
Conditions:
Impaired Glucose Tolerance
Diabetes
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
It is now well established that the 21st century will be characterized by a global epidemic of Type 2 diabetes. The principal aim of the CANOE study is to determine whether individuals with the pre-di...
Detailed Description
The CANOE Study CAnadian Normoglycemia Outcomes Evaluation Study It is now well accepted that the 21st Century will be characterized by a global epidemic of Type 2 diabetes mellitus \[Type 2DM\]. To ...
Eligibility Criteria
Inclusion
- Residents of Ontario
- Age 18-75
- IGT on OGTT
Exclusion
- Current use of Metformin or Rosiglitazone
- Prior use of medication to treat diabetes except gestational diabetes
- Use of drugs known to exacerbate glucose tolerance
- History of diabetes except gestational diabetes
- Liver function studies greater the 2.5x normal
- Creatinine clearance less than 60 ml/min
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
207 Patients enrolled
Trial Details
Trial ID
NCT00116922
Start Date
June 1 2004
End Date
January 1 2010
Last Update
May 24 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
UWO Research Park
London, Ontario, Canada, N6G 4X8
2
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5